Xeris Pharma (XERS) Enterprise Value to EBITDA Ratio

Public company logo of xerispharma.com (XERS)

Patented injection formulas provide Xeris Biopharma (XERS) with steady revenue, while high capacity utilization eliminates downtime. The Enterprise Value to EBITDA multiple reflects market expectations, with the current metric standing at 53.07. Meanwhile, cash flow predictability is increasing due to the commercialization of specialized drugs for the treatment of endocrine pathologies, which stabilizes the company's financial position.

Xeris Biopharma Holdings, Inc. - XERS Company Value to EBITDA (period 11/23/2025 - 11/14/2026)

Comprehensive metric breakdowns and analytics for Xeris Biopharma Holdings, Inc. (XERS)

- current price and projected stock value:
Stock Price xerispharma.com|XERS - Analyst Median Target
- market capitalization details:
Market Valuation Xeris Biopharma|XERS - Full Business Value
- business book valuation details:
Book Value per Share Xeris Biopharma|XERS - Total Stockholders' Equity|Market Capitalization to Book Value Ratio xerispharma.com|XERS - Total Business Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Xeris Biopharma|XERS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Xeris Biopharma Holdings|XERS - Company Aggregate Indebtedness|Debts to Book Capitalization Xeris Biopharma Holdings, Inc.|XERS - Company Long-Term Loans and Borrowings|Company Short-Term Debts Xeris Biopharma|Quick Liquidity xerispharma.com
- financial results and valuation multiples details:
XERS - Final Profit|Expected Profit Xeris Biopharma|XERS - Price to Earnings Ratio|Forward P/E Multiple xerispharma.com|XERS - PEG Multiple|Enterprise Value to EBITDA Ratio Xeris Biopharma Inc|XERS - Operating profit before amortization|Net earnings per share (EPS TTM) Xeris Biopharma|XERS - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months xerispharma.com|XERS - Earnings per share increase in current year|Earnings growth forecast for next year Xeris Biopharma
- revenue and sales details:
XERS - Company Gross Revenue|Company Projected Revenue xerispharma.com|XERS - Price-to-Revenue Coefficient|Forward Price-to-Revenue Multiple Xeris Biopharma Holdings, Inc.
Fundamental valuation:Xeris Biopharma XERS
Manufactured products of Xeris Biopharma Holdings

The EV/EBITDA ratio compares the total enterprise value, including debt load, with operational efficiency before taxes and amortization. The strong pricing power of Xeris Biopharma (XERS) in emergency medicine, driven by XeriSol technology, supports a stable cash flow, which allows the company's current EV/EBITDA level on the GURU.Markets platform to determine the degree of asset undervaluation relative to its fundamental ability to generate profit.

Key competitors

EV/EBITDA Multiple VRTX (vrtx.com)|Total Company Value to Operating Income Before Depreciation Ratio Alnylam (ALNY)|INSM: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio UTHR|BMRN: EV/EBITDA Multiple|Company Value to EBITDA BridgeBio Pharma Inc (BBIO)|Enterprise Value to EBITDA Ratio BGM|Enterprise Value to Operating Income Before Depreciation COGT (Cogent Biosciences, Inc.)|Enterprise Value to EBITDA Ratio KROS (Keros Therapeutics, Inc.)|ARCT (Arcturus Therapeutics Inc) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Eton Pharmaceuticals, Inc. ETON|KMDA (Kamada Corp) - Company Value to Operating Income Before Depreciation Ratio|Fulcrum Therapeutics - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation ABEO (abeonatherapeutics.com)|MREO: EV/EBITDA Multiple|Protalix BioTherapeutics Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization pliantrx.com|APLT: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization aileronrx.com (RNTX)|Enterprise Value to EBITDA Ratio Gelteq GELS|EV/EBITDA Multiple AYTU (Aytu BioPharma Inc)|EV/EBITDA Multiple Chemomab CMMB|SRXH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio PLRZ|AEZS: EV/EBITDA Multiple|Company Value to EBITDA Cyclo Therapeutics (CYTH)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inozyme Pharma Inc.|Enterprise Value to Operating Income Before Depreciation RPHM (Reneo Pharmaceuticals, Inc.)|EV/EBITDA Multiple CSCI